Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study

Key Points

• Topical GT20029 demonstrated significant efficacy in hair regrowth with good tolerability, enhancing treatment options.
• A double-blind, placebo-controlled phase 2 study evaluated the effects of topical GT20029 in male patients.
• The multicenter design allows for diverse patient recruitment, increasing generalizability of results.
• Further studies are warranted to confirm its therapeutic potential in androgenetic alopecia.